FDA calendar · January 2023 · built from SEC filings

PDUFA dates January 2023: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in January 2023. The FDA calendar also recorded 26 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in January 2023

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

January 2023: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Jan 2023Month disclosedWEZLANA® (ustekinumab)ALVONDA/BLA accepted—Completedsec_424b
Jan 2023Month disclosedJanuvia (sitagliptin)MRKFDA approval—ApprovedSEC Form 10-Q
Jan 2023Month disclosedPT027RPRXFDA approval—ApprovedSEC Form 10-Q
January 5, 2023TH103KLRSFDA approval—ApprovedSEC 8-K Exhibit 99.1
January 10, 2023Airsupra (albuterol sulfate; budesonide)AZNFDA approval—ApprovedopenFDA Drugs@FDA
January 13, 2023Epzicom (abacavir sulfate; lamivudine)VTRSComplete Response Letter—CRL issuedFDA Complete Response Letters
January 18, 2023Kisunla (donanemab-azbt)LLYComplete Response Letter—CRL issuedFDA Complete Response Letters
January 19, 2023DARZALEX (daratumumab)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
January 19, 2023BRUKINSA® (zanubrutinib)ONCLabel expansion—ApprovedopenFDA Drugs@FDA
January 19, 2023Tukysa (tucatinib)PFELabel expansion—ApprovedopenFDA Drugs@FDA
January 20, 2023Soluprep S (chlorhexidine gluconate; isopropyl alcohol)SOLVLabel expansion—ApprovedopenFDA Drugs@FDA
January 25, 2023Dovato (dolutegravir sodium; lamivudine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
January 25, 2023Entyvio® (vedolizumab)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
January 26, 2023KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
January 27, 2023Jaypirca (pirtobrutinib)LLYFDA approval—ApprovedFDA Novel Drug Approvals
January 31, 2023Revatio® (sildenafil)VTRSLabel expansion—ApprovedopenFDA Drugs@FDA

January 2023: dated readouts

DateDrugCompanyEventIndicationStatusSource
Jan 2023Month disclosedRYTELO (imetelstat)GERNTopline readout—PositiveSEC Form 10-Q
Jan 2023Month disclosedNERD-301PHATTopline readoutNon-Erosive reflux disease, or Non-Erosive GERDPositiveSEC Form 10-K
Jan 2023Month disclosedTRUTAKNA (atacicept)VERATopline readout—Positivesec_424b
Jan 2023Month disclosed—VERATopline readout—PositiveSEC Form 10-K
January 12, 2023—ORMPTopline readout—Missed primary endpointSEC Form 10-K
January 19, 2023OXY-101XRTXTopline readout—PositiveSEC 8-K Exhibit 99.1
January 27, 2023—LEGNInterim readout—Met primary endpointSEC Form 10-K

January 2023: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Jan 2023Month disclosedMP0533MOLNTrial startr/r AML and AML/MDSCompletedSEC Form 10-K
Jan 2023Month disclosedaleniglipron (GSBR-1290)GPCRTrial start—CompletedSEC Form 10-Q
January 27, 2023ATR-12AZTRTrial start—Completedsec_s1

Questions

What PDUFA dates are in January 2023?

0 PDUFA dates fell in January 2023. The FDA calendar also recorded 26 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.